250 related articles for article (PubMed ID: 33656739)
21. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Genovese MC; Greenwald M; Codding C; Zubrzycka-Sienkiewicz A; Kivitz AJ; Wang A; Shay K; Wang X; Garg JP; Cardiel MH
Arthritis Rheumatol; 2017 May; 69(5):932-942. PubMed ID: 28118538
[TBL] [Abstract][Full Text] [Related]
22. Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Zhu T; Moy S; Valluri U; Cao Y; Zhang W; Sawamoto T; Chindalore V; Akinlade B
Clin Drug Investig; 2020 Sep; 40(9):827-838. PubMed ID: 32591978
[TBL] [Abstract][Full Text] [Related]
23. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.
Gao X; He X; Oshima H; Miyatake D; Otsuka Y; Kato K; Cai C; Wojtkowski T; Song N; Kaneko Y; Shi A
Drug Des Devel Ther; 2022; 16():1365-1381. PubMed ID: 35586186
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Miyatake D; Shibata T; Shibata M; Kaneko Y; Oda K; Nishimura T; Katashima M; Sekino H; Furihata K; Urae A
Clin Drug Investig; 2020 Feb; 40(2):149-159. PubMed ID: 31729626
[TBL] [Abstract][Full Text] [Related]
28. Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
Arthritis Res Ther; 2020 Jun; 22(1):155. PubMed ID: 32576246
[TBL] [Abstract][Full Text] [Related]
29. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
[TBL] [Abstract][Full Text] [Related]
31. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Sands BE; Sandborn WJ; Feagan BG; Lichtenstein GR; Zhang H; Strauss R; Szapary P; Johanns J; Panes J; Vermeire S; O'Brien CD; Yang Z; Bertelsen K; Marano C;
J Crohns Colitis; 2018 Nov; 12(10):1158-1169. PubMed ID: 29917064
[TBL] [Abstract][Full Text] [Related]
32. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Tebib J; Mariette X; Bourgeois P; Flipo RM; Gaudin P; Le Loët X; Gineste P; Guy L; Mansfield CD; Moussy A; Dubreuil P; Hermine O; Sibilia J
Arthritis Res Ther; 2009; 11(3):R95. PubMed ID: 19549290
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
35. Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis.
Tanaka Y; Okumura H; Kim S; Dorey J; Wojciechowski P; Chorąży J; Kato D; Schultz NM
Rheumatol Ther; 2021 Jun; 8(2):729-750. PubMed ID: 33725321
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of peficitinib in rheumatoid arthritis.
Kaneko Y
Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
[TBL] [Abstract][Full Text] [Related]
38. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
39. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
40. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
